Mylan NV (MYL.OQ)
* MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN
* MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION
Indian shares snapped a four-session losing streak to end higher on Monday, as Infosys Ltd climbed on the appointment of a new CEO and hopes that the software services firm would move past a costly boardroom spat.
Dec 4 Indian stocks rose on Monday as Infosys Ltd rallied on hopes that the appointment of a new CEO would help the company move on from a feud between its board and founders that had pummelled shares.
** Biocon Ltd jumps as much as 13.8 pct to hit a record high of 509.00 rupees
The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.
* FDA APPROVAL OF HEPARIN SODIUM INJECTION CONTINUES TO DEMONSTRATE MYLAN'S DEEP EXPERTISE IN DEVELOPING COMPLEX PRODUCTS
Dec 1 The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster breast cancer treatment Herceptin.
BUZZ-India's Biocon hits record high; EU regulator OKs marketing applications for generic cancer drugs
** Biocon Ltd jumped as much as 3.6 pct to touch a record high of 447.60 rupees
* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM